Vectura CEO to step down at end of June
pharmafile | June 10, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | appointment, pharma, vectura
Vectura is on course for a new leader to take up the company’s reins after it was revealed that CEO James Ward-Lilley is to step down from his role on 30 June.
During his time at the head of the company, Ward-Lilley served Vectura at a “critical time”, the company said, and this included presiding over its merger with Skyepharma. Prior to this, he spent 28 years in roles of increasing seniority at AstraZeneca.
“I would like to express my sincere thanks to James for his distinguished leadership of the Group. Following the successful merger with Skyepharma in 2016, James has demonstrated great resilience building an effective and robust business,” remarked Bruno Angelici, Chairman of the Board at Vectura. “This has been reflected in strong 2018 financial and operational performance, followed by positive news flow this year. During his time he has also built a culture of effective employee engagement and a significantly strengthened and talented team. The Board and James have agreed that after four years as CEO it is now time for a new leader to take Vectura through its next phase of development. We look forward, in due course, to announcing the appointment of a new CEO.”
Chief Financial Officer Paul Fry has been confirmed to be taking over as CEO in the interim while a successor can be found. The search for a new CEO has already begun.
Speaknig on his own appointment, Ward-Lilley commented: “The strong results delivered in 2018 and the positive start made to 2019 underline today’s Vectura as a growing, cash generative business with a strong balance sheet and positive pipeline momentum. I am proud to have led the business over the past four years as CEO particularly through the transformational integration with Skyepharma. I will leave Vectura in a strong operational and financial position with a robust leadership team as the Group enters the next phase of its evolution. I would like to thank Vectura’s industry-leading employees who have made the Group what it is today. It has been a privilege to work with them.”
Matt Fellows
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
Novartis acquires Chinook Therapeutics for $3.5bn
Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …
